IL310894A - Milovacian for the prevention and treatment of thromboembolic disorders - Google Patents
Milovacian for the prevention and treatment of thromboembolic disordersInfo
- Publication number
- IL310894A IL310894A IL310894A IL31089424A IL310894A IL 310894 A IL310894 A IL 310894A IL 310894 A IL310894 A IL 310894A IL 31089424 A IL31089424 A IL 31089424A IL 310894 A IL310894 A IL 310894A
- Authority
- IL
- Israel
- Prior art keywords
- daily dose
- milvexian
- pharmaceutically acceptable
- acceptable salt
- administered
- Prior art date
Links
- FSWFYCYPTDLKON-CMJOXMDJSA-N (9R,13S)-13-[4-[5-chloro-2-(4-chlorotriazol-1-yl)phenyl]-6-oxopyrimidin-1-yl]-3-(difluoromethyl)-9-methyl-3,4,7,15-tetrazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one Chemical compound C[C@@H]1CCC[C@H](N2C=NC(=CC2=O)C2=C(C=CC(Cl)=C2)N2C=C(Cl)N=N2)C2=NC=CC(=C2)C2=C(NC1=O)C=NN2C(F)F FSWFYCYPTDLKON-CMJOXMDJSA-N 0.000 title claims 41
- 229940073199 milvexian Drugs 0.000 title claims 41
- 230000009424 thromboembolic effect Effects 0.000 title claims 13
- 230000002265 prevention Effects 0.000 title 1
- 238000000034 method Methods 0.000 claims 38
- 150000003839 salts Chemical class 0.000 claims 36
- 206010014522 Embolism venous Diseases 0.000 claims 16
- 208000004043 venous thromboembolism Diseases 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 208000035475 disorder Diseases 0.000 claims 12
- 238000001356 surgical procedure Methods 0.000 claims 6
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 4
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 4
- 206010047249 Venous thrombosis Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229960000610 enoxaparin Drugs 0.000 claims 4
- 230000002980 postoperative effect Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- 208000032843 Hemorrhage Diseases 0.000 claims 2
- 238000012084 abdominal surgery Methods 0.000 claims 2
- 208000034158 bleeding Diseases 0.000 claims 2
- 230000000740 bleeding effect Effects 0.000 claims 2
- 231100000673 dose–response relationship Toxicity 0.000 claims 2
- 238000011540 hip replacement Methods 0.000 claims 2
- 238000013150 knee replacement Methods 0.000 claims 2
- 239000006186 oral dosage form Substances 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims 1
- 229940054136 kineret Drugs 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163245522P | 2021-09-17 | 2021-09-17 | |
| US202163278582P | 2021-11-12 | 2021-11-12 | |
| PCT/US2022/043797 WO2023043999A1 (en) | 2021-09-17 | 2022-09-16 | Milvexian for prevention and treatment of thromboembolic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL310894A true IL310894A (en) | 2024-04-01 |
Family
ID=83688923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL310894A IL310894A (en) | 2021-09-17 | 2022-09-16 | Milovacian for the prevention and treatment of thromboembolic disorders |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250099466A1 (https=) |
| EP (1) | EP4401736A1 (https=) |
| JP (1) | JP2024534427A (https=) |
| KR (1) | KR20240060820A (https=) |
| AU (1) | AU2022345862A1 (https=) |
| CA (1) | CA3232633A1 (https=) |
| CL (1) | CL2024000776A1 (https=) |
| IL (1) | IL310894A (https=) |
| MX (1) | MX2024002857A (https=) |
| TW (1) | TW202327607A (https=) |
| WO (1) | WO2023043999A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA71692A (fr) * | 2022-08-01 | 2025-05-30 | Bristol-Myers Squibb Company | Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémique |
| TW202506125A (zh) * | 2023-04-19 | 2025-02-16 | 美商必治妥美雅史谷比公司 | 米爾維仙(milvexian)於治療及預防患有心血管或腦血管疾病之患者之血栓病況的用途 |
| WO2024220803A1 (en) * | 2023-04-19 | 2024-10-24 | Bristol-Myers Squibb Company | Use of milvexian in the treatment and prevention of thrombotic conditions in patients with atrial fibrilation |
| EP4698172A1 (en) * | 2023-04-19 | 2026-02-25 | Bristol-Myers Squibb Company | Use of milvexian for treating or preventing adverse cerebrovascular events or adverse cardiovascular events in patients having acute coronary syndrome |
| WO2025126240A1 (en) * | 2023-12-12 | 2025-06-19 | Dr. Reddy's Laboratories Limited | Pharmaceutical compositions and use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9453018B2 (en) * | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| BR112021020257A2 (pt) | 2019-04-11 | 2021-12-07 | Bristol Myers Squibb Co | Desempenho intensificado de sólido amorfo e formulações solubilizadas para realizar concentrações de plasma terapêutico |
-
2022
- 2022-09-16 IL IL310894A patent/IL310894A/en unknown
- 2022-09-16 US US18/692,560 patent/US20250099466A1/en active Pending
- 2022-09-16 JP JP2024516849A patent/JP2024534427A/ja active Pending
- 2022-09-16 KR KR1020247012366A patent/KR20240060820A/ko active Pending
- 2022-09-16 TW TW111135090A patent/TW202327607A/zh unknown
- 2022-09-16 CA CA3232633A patent/CA3232633A1/en active Pending
- 2022-09-16 AU AU2022345862A patent/AU2022345862A1/en active Pending
- 2022-09-16 WO PCT/US2022/043797 patent/WO2023043999A1/en not_active Ceased
- 2022-09-16 EP EP22786640.7A patent/EP4401736A1/en active Pending
- 2022-09-16 MX MX2024002857A patent/MX2024002857A/es unknown
-
2024
- 2024-03-15 CL CL2024000776A patent/CL2024000776A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2024000776A1 (es) | 2024-07-26 |
| AU2022345862A1 (en) | 2024-03-14 |
| JP2024534427A (ja) | 2024-09-20 |
| KR20240060820A (ko) | 2024-05-08 |
| EP4401736A1 (en) | 2024-07-24 |
| CA3232633A1 (en) | 2023-03-23 |
| US20250099466A1 (en) | 2025-03-27 |
| WO2023043999A1 (en) | 2023-03-23 |
| TW202327607A (zh) | 2023-07-16 |
| MX2024002857A (es) | 2024-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL310894A (en) | Milovacian for the prevention and treatment of thromboembolic disorders | |
| Shetty et al. | A prospective randomized study to analyze the efficacy of balanced pre-emptive analgesia in spine surgery | |
| JP2024534427A5 (https=) | ||
| KR100516676B1 (ko) | 안면 수술에서의 레보부피바카인의 용도 | |
| JP2017510607A5 (https=) | ||
| MX2024010637A (es) | Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| CA2313270A1 (en) | Use of deferiprone in treating and preventing iron-induced cardiac disease | |
| JP2025148449A5 (https=) | ||
| MX2024006270A (es) | Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JP2010106019A (ja) | リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤 | |
| KR20160080111A (ko) | 경추 및 요추 질환 치료용 약물 | |
| US9545419B1 (en) | Method and compositions for treating chronic inflammatory disorders | |
| RU2006139819A (ru) | Применение симетикона для предрасположенных к запорам пациентов | |
| KR102927058B1 (ko) | 진통 가려움 완화 약학 조성물 및 그 응용 방법 | |
| US6194460B1 (en) | Composition for treating cough induced by angiotensin converting enzyme inhibitors | |
| Sharma et al. | Comparative study of preclosure periportal instillation of three different concentrations of ropivacaine (0.125%, 0.25%, 0.5%) for postoperative analgesia in laparoscopic cholecystectomy | |
| Beute | (Oral) enoximone in asthma | |
| Chandawat et al. | Role of tamsulosin in the management of lower ureteric stone at tertiary care hospital in Western Rajasthan, India | |
| CN107468917B (zh) | 一种化痰解毒治疗冠心病的中药组合物及其应用 | |
| RU2023116805A (ru) | 5'-o-фенилацетилуридин и терапевтическое применение | |
| Sidani et al. | A237 IMPROVEMENT IN ABDOMINAL SYMPTOMS WITH LINACLOTIDE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION: RESULTS FROM A PHASE 3B TRIAL | |
| SU1382478A1 (ru) | Способ лечени экстрапирамидных заболеваний | |
| CN1682715A (zh) | 一种抗缺氧药物组合物 | |
| CN121550202A (zh) | 索法酮作为trpv3抑制剂在制备治疗皮肤疾病药物中的应用 | |
| CN115381852A (zh) | 一种具有治疗胶质瘤作用的复方药物组合及其用途 |